Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
D-ornithine 4,5-aminomutase (OAM) is a specialized bacterial enzyme responsible for the anaerobic fermentation of amino acids in various microorganisms, including the human pathogen Clostridioides difficile [UniProt, PMID: 28325765]. It catalyzes the reversible intramolecular migration of the delta-amino group of D-ornithine to the C4 position, producing (2R,4S)-2,4-diaminopentanoate [PMID: 18997010, 21899873]. This complex transformation involves a radical-based mechanism that requires two essential cofactors: adenosylcobalamin (coenzyme B12), which generates the initiating 5'-deoxyadenosyl radical, and pyridoxal 5'-phosphate (PLP), which stabilizes the substrate as a Schiff base [PMID: 18997010, 21899873]. Structurally, the enzyme typically exists as a heterotetramer composed of alpha and beta subunits, often designated as OraS and OraE [UniProt, PMID: 18997010]. Because OAM is vital for the metabolic fitness of anaerobic pathogens and is absent in humans, it is viewed as a potential target for the development of selective anti-infective agents [PMID: 28325765]. Experimental inhibitors like 2,4-diaminobutyric acid (DAB) disrupt the catalytic cycle by forming stable radical intermediates that prevent enzyme turnover [PMID: 21899873].
Radical-mediated 1,2-migration of the delta-amino group of D-ornithine to the C4 position using adenosylcobalamin and pyridoxal phosphate cofactors; suicide inhibition occurs through the formation of overstabilized radical intermediates.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on D-ornithine 4,5-aminomutase (OAM).